To better understand the potential side effects of FcRn-silenced IL-12Fc, we compared tumor-naïve C3H/HeJ mice receiving two intraparenchymal doses of either 1 μg or 5 μg mIL-12hFc WT, mIL-12hFc NHQ, or rmIL-12, 7 days apart (Fig. S6A). This evidence concerns the gene FCGRT and neoplasm.